含奥沙利铂方案介入治疗中晚期肝癌的疗效观察

Clinical results of oxaliplatin-containing regimen in the TACE of advanced hepatocellular carcinoma

目的观察含奥沙利铂方案介入治疗中晚期肝癌的疗效和不良反应.方法对79例中晚期肝癌患者在肝动脉中灌注奥沙利铂、表阿霉素、5-氟脲嘧啶,每例完成2～3次后评价疗效及不良反应.结果 79例中完全有效(CR)3例(3.8%),部分有效(PR)54例(68.4%),稳定(SD)16例(20.2%),进展(PD)6例(7.6%),总有效率(CR+PR)为72.2%(57/79).甲胎蛋白下降幅度为73.3%(33/45).主要不良反应为胃肠道反应及骨髓抑制.结论含奥沙利铂方案介入治疗中晚期肝癌具有较高的疗效,不良反应发生率低.

Objective To evaluate the short term activity and toxicity of oxaliplatin-containing regimen in the TACE of advanced hepatocellular carcinoma patients. Methods Seventy-nine advanced hepatocellular carcinoma patients were treated with oxaliplatin, epirubici（EPI） and 5-fluorouracil（5-Fu） through intra-arterial hepatic administration. The short term activity and toxicity were studied after 2-3 times treatment. Results Among them,3 cases were in complete response （CR）（3. 8%） ;54 cases were in partial response（PR） （68.4 % ） ; 16 cases were stable（SD） （20.2 % ） ; 6 cases were in progress（PD） （7.6 % ） ;Total efficiency rate（CR＋PR） was 72.0%（57/79）. The rate of descent of AFP was 73.3% （33/45）. The major side effects were digestive tract side effect and leukopenia. Conclusion Oxaliplatin-containing regimen in the TACE of advanced hepatocellular carcinoma patients is an efficient method with few side effects.